Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Aurobindo Pharma...

    Aurobindo Pharma shares fall 3% after Q2 earnings

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-15T09:45:59+05:30  |  Updated On 15 Nov 2018 9:45 AM IST
    Aurobindo Pharma shares fall 3% after Q2 earnings




    New Delhi: Shares of Aurobindo Pharma has recently fallen almost 3 per cent after the company reported 21.70 per cent dip in consolidated net profit for the quarter ended September 30, 2018. The stock went down 2.96 per cent to end at Rs 774.70 on BSE. During the day, it declined 4.76 per cent to Rs 760.25.

    On NSE, shares of the company dropped 2.63 per cent to close at Rs 775.

    Aurobindo Pharma Monday reported 21.70 per cent dip in consolidated net profit to Rs 611.44 crore for the September quarter, mainly on account of rise in expenses.

    The company had posted a net profit of Rs 780.97 crore in the year-ago period, Aurobindo Pharma said in a BSE filing.

    Consolidated total revenue from operations stood at Rs 4,751.40 crore for the quarter under review. It was Rs 4,435.89 crore in the same period last year.

    Total expenses stood at Rs 3,964.20 crore for the reported quarter. It was Rs 3,468.36 crore during the same period of 2017-18.





    Read Also: Aurobindo Pharma Issues Voluntary Recall of Irbesartan Drug: FDA



    AurobindoAurobindo PharmaearningNSEQ2shares of aurobindo
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok